MX2022005465A - Metodos de tratamiento con modulador de miosina. - Google Patents

Metodos de tratamiento con modulador de miosina.

Info

Publication number
MX2022005465A
MX2022005465A MX2022005465A MX2022005465A MX2022005465A MX 2022005465 A MX2022005465 A MX 2022005465A MX 2022005465 A MX2022005465 A MX 2022005465A MX 2022005465 A MX2022005465 A MX 2022005465A MX 2022005465 A MX2022005465 A MX 2022005465A
Authority
MX
Mexico
Prior art keywords
myosin
treatment
methods
mavacamten
modulator
Prior art date
Application number
MX2022005465A
Other languages
English (en)
Inventor
Robert Mcdowell
Timothy Carlson
Marc J Semigran
Joseph Lambing
Rio Carlos L Del
Jay M Edelberg
Sarah Fernandes
Marcus Patrick Henze
Grace Yanfei Ma
Matthew Edwards Mealiffe
Amy Sehnert
Kathy L Lampl
David Zhang
Milind Y Desai
Steve Nissen
Liang Fang
Wanying Li
Danielle L Aubele
Brian Edmund Kane
Louis Charles Sehl
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of MX2022005465A publication Critical patent/MX2022005465A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen métodos de tratamiento que comprenden administrar una cantidad terapéuticamente eficaz de un modulador de la miosina o una sal farmacéuticamente aceptable de este a un sujeto que lo necesite y métodos de diagnóstico útiles en relación con esos tratamientos. Debido a observaciones desarrolladas en ensayos clínicos con mavacamten y con mavacamten y otros inhibidores de la miosina en el ámbito preclínico, en la presente se proporcionan nuevos conocimientos sobre cómo pueden usarse los inhibidores de la miosina de manera beneficiosa para influir en el grado de actividad de la HCM y otras enfermedades.
MX2022005465A 2019-11-10 2020-11-10 Metodos de tratamiento con modulador de miosina. MX2022005465A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962933517P 2019-11-10 2019-11-10
US201962933970P 2019-11-11 2019-11-11
US201962935922P 2019-11-15 2019-11-15
US202063001473P 2020-03-29 2020-03-29
US202063002302P 2020-03-30 2020-03-30
US202063006701P 2020-04-07 2020-04-07
US202063022573P 2020-05-10 2020-05-10
US202063059143P 2020-07-30 2020-07-30
US202063064450P 2020-08-12 2020-08-12
PCT/US2020/059893 WO2021092598A1 (en) 2019-11-10 2020-11-10 Methods of treatment with myosin modulator

Publications (1)

Publication Number Publication Date
MX2022005465A true MX2022005465A (es) 2022-08-08

Family

ID=75849342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005465A MX2022005465A (es) 2019-11-10 2020-11-10 Metodos de tratamiento con modulador de miosina.

Country Status (13)

Country Link
US (1) US20230158027A1 (es)
EP (1) EP4054588A4 (es)
JP (1) JP2023501453A (es)
KR (1) KR20220113387A (es)
CN (1) CN114945372A (es)
AU (1) AU2020378197A1 (es)
BR (1) BR112022008641A2 (es)
CA (1) CA3157629A1 (es)
CL (1) CL2022001217A1 (es)
IL (1) IL292840A (es)
MX (1) MX2022005465A (es)
TW (1) TW202134259A (es)
WO (1) WO2021092598A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003496A2 (pt) 2018-08-31 2021-05-18 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para tratar doença cardíaca, para tratar uma doença ou afecção associada à cardiomiopatia hipertrófica, ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, ou afecção que está associada à pequena cavidade do ventículo esquerdo e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, ou afecção selecionada dentre distrofias musculares e doenças de armazenamento de glicogênio, para inibir o sarcômero cardíaco
KR20230079053A (ko) * 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
CN115461052B (zh) * 2020-11-25 2023-12-22 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) * 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
IL310140A (en) * 2021-07-16 2024-03-01 Cytokinetics Inc Methods for treating hypertrophic cardiomyopathy
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
WO2023199258A1 (en) 2022-04-13 2023-10-19 Teva Pharmaceuticals International Gmbh Solid state forms of mavacamten and process for preparation thereof
US20230338378A1 (en) * 2022-04-26 2023-10-26 MyoKardia, Inc. Methods of Administering Myosin Inhibitors
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170188978A1 (en) * 2016-01-04 2017-07-06 AventuSoft, LLC System and method of measuring hemodynamic parameters from the heart valve signal
AU2018311974B2 (en) * 2017-08-04 2024-03-07 MyoKardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Also Published As

Publication number Publication date
JP2023501453A (ja) 2023-01-18
US20230158027A1 (en) 2023-05-25
EP4054588A4 (en) 2023-12-13
BR112022008641A2 (pt) 2022-09-13
CA3157629A1 (en) 2021-05-14
IL292840A (en) 2022-07-01
TW202134259A (zh) 2021-09-16
AU2020378197A1 (en) 2022-05-26
CN114945372A (zh) 2022-08-26
EP4054588A1 (en) 2022-09-14
CL2022001217A1 (es) 2023-01-13
WO2021092598A1 (en) 2021-05-14
KR20220113387A (ko) 2022-08-12

Similar Documents

Publication Publication Date Title
MX2022005465A (es) Metodos de tratamiento con modulador de miosina.
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
MX2023002024A (es) Métodos de tratamiento con modulador de miosina.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
JP2015519329A5 (es)
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
PH12020551555A1 (en) Calpain modulators and therapeutic uses thereof
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2020001342A (es) Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX2022003945A (es) Metodo para tratar vih con cabotegravir y rilpivirina.
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
Rodda et al. Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer
Kumar et al. An observational study to compare the outcome of local steroid injections and ultrasonic wave therapy in frozen shoulder patients
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
ZA202006986B (en) Dantrolene formulations and methods of their use
WO2019210320A3 (en) Methods and compositions to stimulate retinal regeneration
AR109760A1 (es) Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson
WO2014023869A3 (es) Aplicacion terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana
CA3104253A1 (en) Use of arimoclomol in the treatment of niemann pick disease
WO2023019095A3 (en) Momelotinib combination therapy
WO2019222130A8 (en) Combination treatment with antibody-drug conjugates and flt3 inhibitors
Li EFFECTS OF ELECTROACUPUNCTURE AND MASSAGE IN REDUCING THE RECURRENCE RATE OF EXTERNAL HUMERAL EPICONDYLITIS